GlassScriptPhysician profile
Cedric L Harris
NPI 1770644031
$8,916.60
in general payments reported to CMS, 2019-2025
43 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $547 · 2020: $296 · 2021: $1,376 · 2022: $1,918 · 2023: $1,644 · 2024: $1,721 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,770 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,770.30 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,622.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,188.35 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $951.91 | 2021-2025 | |
| Pfizer INC. | $639.38 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $619.08 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $561.53 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $400.19 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $383.41 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.86 | 2020-2024 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $246.29 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $204.77 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Esperion Therapeutics, INC. | $162.25 | 2020-2025 | Nexletol |
| Axsome Therapeutics, INC. | $134.94 | 2025 | Auvelity |
| Xeris Pharmaceuticals, INC. | $116.54 | 2025 | Recorlev |
| Exact Sciences Corporation | $110.65 | 2023-2025 | Cologuard Collection Kit |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cedric Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.